New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:59 EDTBLUEbluebird bio announces data from HGB-205 clinical study
bluebird bio on Saturday released initial clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects. The company said the clinical update provided on two subjects treated in the prior LG001 Study using the prior lentiviral HPV569 product candidate; Subject 3 remains blood transfusion independent 72 months after being transplanted with the lentiviral HPV569 product candidate; Subjects 3 and 4 are producing 2.7 g/dL and 0.4 g/dL of therapeutic beta A-T87Q-globin post-transplant, respectively; No drug product related adverse events were reported in the LG001 Study. The company sees reporting additional data from the HGB-205 Study and from our ongoing Northstar Study in late 2014.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use